In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 4.13 a new company low.

Within Major Pharmaceutical Preparations industry 190 other companies have achieved higher Quick Ratio than Metsera Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 65 to 644.

Explain Quick Ratio?
How much Cash & cash equivalents MTSR�s has?
What are MTSR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MTSR Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Dec 31 2023) Q3
Y / Y Current Liabilities Change	519.4 %	-	-	-	-
Y / Y Cash & cash equivalent Change	496.4 %	-	-	-	-
Quick Ratio MRQ	4.13	5.19	6.48	5.24	4.29
MTSR's Total Ranking	# 644	# 65	# 391	# 0	#
Seq. Current Liabilities Change	6.05 %	12.75 %	34.82 %	284.26 %	-
Seq. Cash & cash equivalent Change	-15.53 %	-9.76 %	66.93 %	368.71 %	-

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 191
Healthcare Sector	# 319
Overall Market	# 644

Quick Ratio Statistics
High	Average	Low
6.48	5.26	4.13
(Mar 31 2025)		(Sep 30 2025)

Financial Statements
Metsera Inc 's Current Liabilities	$ 108 Millions	Visit MTSR's Balance sheet
Metsera Inc 's Cash & cash equivalent	$ 448 Millions	Visit MTSR's Balance sheet
Source of MTSR's Sales		Visit MTSR's Sales by Geography

Cumulative Metsera Inc 's Quick Ratio

MTSR's Quick Ratio for the trailling 12 Months

MTSR Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	2005.79 %	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	2453.58 %	-	-	-	-
Quick Ratio TTM	5.21	5.57	5.79	5.04	4.29
Total Ranking TTM	# 2949	# 0	# 0	# 0	#
Seq. Current Liabilities TTM Growth	32.74 %	58.27 %	106.98 %	384.26 %	-
Seq. Cash & cash equivalent TTM Growth	24.13 %	52.26 %	137.58 %	468.71 %	-

Quick ratio ranking by company, industry and sector >> Back to MTSR Financial Strength Comparisons >> Go to Compare MTSR Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2025 to $108.49 millions, cumulative Quick Ratio decreased to 5.21 below the Metsera Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Metsera Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 0 to 2949.

Explain Quick Ratio?
How much Cash & cash equivalents MTSR�s has?
What are MTSR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 407
Healthcare Sector	# 835
Within the Market	# 2949

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.21	5.21	5.21
(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Onkure Therapeutics Inc	11.26	$ 70.331 Millions	$ 6.247 Millions
Palvella Therapeutics Inc	11.16	$ 63.567 Millions	$ 5.697 Millions
Harmony Biosciences Holdings inc	10.83	$ 672.581 Millions	$ 62.101 Millions
Diamedica Therapeutics Inc	10.76	$ 55.518 Millions	$ 5.159 Millions
Anebulo Pharmaceuticals Inc	10.74	$ 10.355 Millions	$ 0.964 Millions
Nuvalent Inc	10.58	$ 943.103 Millions	$ 89.151 Millions
Spyre Therapeutics Inc	10.51	$ 486.198 Millions	$ 46.274 Millions
Pmv Pharmaceuticals Inc	10.50	$ 129.250 Millions	$ 12.304 Millions
Cartesian Therapeutics Inc	10.39	$ 143.384 Millions	$ 13.803 Millions
Eledon Pharmaceuticals Inc	10.34	$ 183.132 Millions	$ 17.718 Millions
Erasca Inc	10.04	$ 288.400 Millions	$ 28.712 Millions
Lyell Immunopharma Inc	10.03	$ 319.624 Millions	$ 31.878 Millions
Edesa Biotech Inc	10.01	$ 10.800 Millions	$ 1.079 Millions
Oramed Pharmaceuticals Inc	10.00	$ 61.173 Millions	$ 6.119 Millions
Boundless Bio Inc	9.93	$ 117.570 Millions	$ 11.845 Millions
Innoviva Inc	9.83	$ 476.513 Millions	$ 48.471 Millions
Abivax Sa	9.80	$ 692.017 Millions	$ 70.584 Millions
Medicinova Inc	9.76	$ 32.563 Millions	$ 3.337 Millions
Vtv Therapeutics Inc	9.72	$ 98.504 Millions	$ 10.131 Millions
Astria Therapeutics Inc	9.68	$ 227.721 Millions	$ 23.517 Millions
Merus N v	9.52	$ 826.363 Millions	$ 86.800 Millions
Lite Strategy Inc	9.47	$ 10.113 Millions	$ 1.068 Millions
Bicycle Therapeutics Plc	9.36	$ 648.325 Millions	$ 69.282 Millions
Abeona Therapeutics Inc	9.34	$ 207.117 Millions	$ 22.180 Millions
An2 Therapeutics Inc	9.28	$ 61.921 Millions	$ 6.675 Millions
Mineralys Therapeutics Inc	9.25	$ 217.597 Millions	$ 23.520 Millions
Silo Pharma Inc	9.22	$ 5.866 Millions	$ 0.636 Millions
Bioage Labs Inc	9.21	$ 225.651 Millions	$ 24.493 Millions
Neuphoria Therapeutics Inc	9.21	$ 13.650 Millions	$ 1.483 Millions
Tonix Pharmaceuticals Holding Corp	9.04	$ 190.055 Millions	$ 21.031 Millions

Date modified: 2026-09-26T07:43:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.